920979-04-0

Basic information

• Product Name: 3-Amino-2-iodo-6-(trifluoromethyl)-pyridine
• Synonyms: 3-Amino-2-iodo-6-(trifluoromethyl)-pyridine;3-Amino-6-iodo-2-trifluoromethylpyridine;5-Amino-6-iodo-2-(trifluoromethyl)pyridine
• CAS NO: 920979-04-0
• Molecular Formula: C₆H₄F₃IN₂
• Molecular Weight: 288.01
• Mol File: 920979-04-0.mol

Chemical Properties

• Boiling Point: 233.1°C at 760 mmHg
• Flash Point: 94.8°C
• Appearance: /
• Density: 1.892g/cm³
• Vapor Pressure: 0.0867mmHg at 25°C
• Refractive Index: 1.586
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 3-Amino-2-iodo-6-(trifluoromethyl)-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-2-iodo-6-(trifluoromethyl)-pyridine(920979-04-0)
• EPA Substance Registry System: 3-Amino-2-iodo-6-(trifluoromethyl)-pyridine(920979-04-0)

Safety Data

• Hazardous Substances Data: 920979-04-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Amino-2-iodo-6-(trifluoromethyl)-pyridine is used as a building block in organic synthesis for the creation of various heterocyclic compounds and functional materials. Its unique structural features and reactivity make it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-Amino-2-iodo-6-(trifluoromethyl)-pyridine is used as a key intermediate in drug design and discovery. Its trifluoromethyl group is particularly advantageous, as fluorine substitutions are known to enhance the stability, solubility, and overall pharmacological profile of drug candidates, potentially leading to improved therapeutic efficacy and safety.
Used in Drug Design and Discovery:
3-Amino-2-iodo-6-(trifluoromethyl)-pyridine is employed as a structural moiety in drug design and discovery, where its unique combination of functional groups can be leveraged to create novel bioactive molecules with enhanced properties. The presence of the trifluoromethyl group can significantly impact the physicochemical and pharmacological characteristics of the resulting compounds, making it a promising candidate for the development of new therapeutic agents.

InChI:InChI=1/C6H5FIN/c1-4-2-3-5(8)6(7)9-4/h2-3H,1H3

Upstream product

• 106877-33-2 6-(trifluoromethyl)pyridin-3-amine 

Downstream Products

• 920979-05-1 (5-trifluoromethyl)pyrrolo[3,2-b]pyridine-2-carboxylic acid 
• 1068971-33-4 2-(3-fluoro-phenyl)-4-methyl-pyrimidine-5-carboxylic acid (3-ethyl-5-trifluoromethyl-pyrrolo[3,2-b]pyridin-1-yl)-amide 
• 1314841-92-3 2-bromomethyl-1-(3-(1,1-dimethylethyl)phenylsulfonyl)-3-methyl-5-trifluoromethyl-1H-pyrrolo[3,2-b]pyridine 
• 1314841-91-2 4-[[1-[[3-(1,1-dimethylethyl)phenyl]sulfonyl]-3-methyl-5-(trifluoro-methyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]methyl]benzoic acid 
• 1314841-90-1 1-(3-(1,1-dimethylethyl)phenylsulfonyl)-2,3-dimethyl-5-trifluoro-methyl-1H-pyrrolo[3,2-b]pyridine 
• 1314841-50-3 2-[1-(3-(1,1-dimethylethyl)phenylsulfonyl)-5-trifluoromethyl-1H-pyrrolo[3,2-b]pyridin-2-yl]thioacetamide 
• 1314841-49-0 [1-(3-(1,1-dimethylethyl)phenylsulfonyl)-5-trifluoromethyl-1H-pyrrolo[3,2-b]pyridin-2-yl]acetonitrile 
• 1314186-71-4 3-(1,1-dimethylethyl)-N-(2-iodo-6-trifluoromethylpyridin-3-yl)benzenesulfonamide 
• 1314841-36-5 2-bromomethyl-1-(3-(1,1-dimethylethyl)phenylsulfonyl)-5-trifluoro-methyl-1H-pyrrolo[3,2-b]pyridine 
• 1314841-35-4 [1-(3-(1,1-dimethylethyl)phenylsulfonyl)-5-trifluoromethyl-1H-pyrrolo[3,2-b]pyridin-2-yl]methanol 
• 1314841-37-6 5-[[1-[[3-(1,1-dimethylethyl)phenyl]sulfonyl]-5-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]methyl]-thiophene-2-carboxylic acid 

Relevant articles and documents

ISOINDOLINES AS HDAC INHIBITORS

The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula: (I) wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.

1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS

The invention is concerned with the compounds of formula I and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.

N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy

The invention relates to compounds of the general formula (I): Wherein X, Y, Z, Z1, Z2, Z3, Z4 and n are as defined herein. The invention also relates to a method for making the same and to the use thereof in th

INHIBITORS OF JUN N-TERMINAL KINASE

The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE

The invention concerns tricyclic N-heteroarylcarboxamide derivatives containing a benzimidazole unit of general formula (I): Wherein A, P, Y, R1, R2 and R3 are as defined herein. The invention also concerns a method of preparing the compounds and their therapeutic use.

Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof

Pyrrolopyridine compounds corresponding to formula (I): as defined in the claims, pharmaceutically acceptable salts thereof, the process for preparing such compounds, pharmaceutical compositions containing such compounds, and their use as pharmacologicall

N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

The invention concerns compounds of general formula (I), wherein n, the pyrrolopyridine ring, X, Z1, Z2, Z3, Z4, Z5 and W are as defined herein. The invention also concerns a method for preparing said compounds and their therapeutic use.